Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Fortress Biotech (FBIO) over the last 13 years, with Q3 2025 value amounting to $0.73.

  • Fortress Biotech's Debt to Equity rose 11779.14% to $0.73 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.73, marking a year-over-year increase of 11779.14%. This contributed to the annual value of $2.55 for FY2024, which is 556.4% down from last year.
  • Fortress Biotech's Debt to Equity amounted to $0.73 in Q3 2025, which was up 11779.14% from $1.14 recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Debt to Equity registered a high of $4.54 during Q1 2023, and its lowest value of -$15.6 during Q1 2024.
  • For the 5-year period, Fortress Biotech's Debt to Equity averaged around -$0.67, with its median value being $0.44 (2022).
  • Over the last 5 years, Fortress Biotech's Debt to Equity had its largest YoY gain of 93413.56% in 2023, and its largest YoY loss of 59057.03% in 2023.
  • Over the past 5 years, Fortress Biotech's Debt to Equity (Quarter) stood at $0.19 in 2021, then soared by 864.64% to $1.83 in 2022, then surged by 47.21% to $2.7 in 2023, then fell by 5.56% to $2.55 in 2024, then plummeted by 71.25% to $0.73 in 2025.
  • Its last three reported values are $0.73 in Q3 2025, $1.14 for Q2 2025, and $1.74 during Q1 2025.